00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
22:18 , Nov 17, 2017 |  BioCentury  |  Emerging Company Profile

New shot at sepsis

Critical Pressure Ltd. is developing a therapy for septic shock to combat hypotension more effectively than marketed vasopressors, and without their side effects. Sepsis is a systemic inflammatory response triggered by severe bacterial infection. Over 30%...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

RI-002 regulatory update

FDA issued a complete response letter to a BLA from ADMA for R1-002, an IV immunoglobulin (IVIG), to treat primary immunodeficiency disease (PIDD). According to ADMA, the agency cited no safety or efficacy concerns and...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers and...
07:00 , May 23, 2016 |  BC Week In Review  |  Financial News

ADMA completes debt financing

ADMA Biologics Inc. (NASDAQ:ADMA), Ramsey, N.J.   Business: Hematology, Infectious   Date completed: 2016-05-13   Type: Debt financing   Raised: $4 million   Investor: Oxford Finance   Note: ADMA drew down an additional $4 million under an amended June 2015 loan...
07:00 , May 9, 2016 |  BC Week In Review  |  Financial News

ADMA financial update

ADMA Biologics Inc. (NASDAQ:ADMA), Ramsey, N.J.   Business: Hematology, Infectious   Date announced: 2016-05-03   Note: ADMA Biologics raised $1.8 million through the sale of 283,846 shares at $6.50 to cover the overallotment from its April 28 follow-on,...
07:00 , May 2, 2016 |  BC Week In Review  |  Financial News

ADMA completes follow-on

ADMA Biologics Inc. (NASDAQ:ADMA), Ramsey, N.J.   Business: Hematology, Infectious   Date completed: 2016-04-28   Type: Follow-on   Raised: $12.3 million   Shares: 1.9 million   Price: $6.50   Shares after offering: 12.6 million   Underwriters: Raymond James; Ladenburg Thalmann   Overallotment: 283,846   ...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

RI-002 regulatory update

FDA accepted for review a BLA from ADMA for RI-002 for patients with primary immunodeficiency. The PDUFA date is in 2H16; AMDA submitted the BLA on July 31. The product is a human plasma-derived, polyclonal,...